Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

S. Nishimura; H. Tsuda; H. Nomura; F. Kataoka; T. Chiyoda; H. Tanaka; K. Tanaka; N. Susumu; D. Aoki

Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

S. Nishimura, H. Tsuda, H. Nomura, F. Kataoka, T. Chiyoda, H. Tanaka, K. Tanaka, N. Susumu, D. Aoki

Research output: Contribution to journal › Article › peer-review

Abstract

For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC.

Original language	English
Pages (from-to)	146-149
Number of pages	4
Journal	European Journal of Gynaecological Oncology
Volume	32
Issue number	2
Publication status	Published - 2011
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Obstetrics and Gynaecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c33136746ccc43119dccaafc45af6498,

title = "Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer",

abstract = "For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC.",

author = "S. Nishimura and H. Tsuda and H. Nomura and F. Kataoka and T. Chiyoda and H. Tanaka and K. Tanaka and N. Susumu and D. Aoki",

year = "2011",

language = "English",

volume = "32",

pages = "146--149",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "S.O.G. CANADA Inc.",

number = "2",

}

TY - JOUR

T1 - Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

AU - Nishimura, S.

AU - Tsuda, H.

AU - Nomura, H.

AU - Kataoka, F.

AU - Chiyoda, T.

AU - Tanaka, H.

AU - Tanaka, K.

AU - Susumu, N.

AU - Aoki, D.

PY - 2011

Y1 - 2011

N2 - For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC.

AB - For both cervical cancer (UCC) and endometrial cancer (EMC) there are no effective prognostic markers. In this study, we evaluated HIG2 protein expression in 332 uterine cancers (186 UCCs and 146 EMCs) and examined the relationship between HIG2 protein expression and clinical factors, including prognosis. Totally, HIG2 expression was detected in 58% of UCC and 66% of EMC. However, there was no significant relationship between HIG2 expression and age, clinical stage and histology in either UCC or EMC. In addition, HIG2 protein expression was not related to prognosis of UCC or EMC. The positivity rate of HIG2 protein was 56% and 61% in early-stage UCC and EMC, respectively and 67% in non-squamous cell carcinoma of UCC. The positivity rate of HIG2 protein was high even in early-stage UCC and EMC.

UR - http://www.scopus.com/inward/record.url?scp=79955684520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955684520&partnerID=8YFLogxK

M3 - Article

C2 - 21614900

AN - SCOPUS:79955684520

SN - 0392-2936

VL - 32

SP - 146

EP - 149

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

IS - 2

ER -

Expression of hypoxia-inducible 2 (HIG2) protein in uterine cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this